1Y Close · As of Aug 26, 2026
Chabiotech operates in the Pharmaceuticals sector.
Legal name: Chabiotech Co.,Ltd.
In fiscal year 2025, Chabiotech (085660) reported revenue of 1.27 trillion KRW, up 21.4% from 1.05 trillion KRW a year earlier.
Operating profit was -48.8 billion KRW and net income was -146.7 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 768.0 billion KRW, with a P/B of 0.95.
These figures can be verified in the DART filing (receipt no. 20260609000370).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 1.3T | -48.8B | -146.7B |
| 2024 | 1.0T | -59.7B | -14.6B |
| 2023 | 954.0B | -9.6B | -5.6B |
| 2022 | 844.6B | -47.1B | -69.7B |
| 2021 | 727.5B | 7.7B | -21.8B |
Recent Filings
Early CB Acquisition (Including Overseas CB)
Acquisition of Other Shares
Semi-Annual Report (2026.06)
Checks
3 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Audit Opinion: Audit opinion: Unqualified (clean).
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-18 | Early CB Acquisition (Including Overseas CB) |
| 2026-08-18 | Acquisition of Other Shares |
| 2026-08-13 | Semi-Annual Report (2026.06) |